Organization · Corporate Venture Capital
Esperante
Esperante is a corporate venture capital firm based in Hoofddorp, Netherlands, specializing in investments in mid to late-stage clinical therapeutics development companies primarily in North America, Europe, and Israel.
Overview
What Esperante does
What Esperante is
Esperante is a corporate venture capital firm based in Hoofddorp, Netherlands, specializing in investments in mid to late-stage clinical therapeutics development companies primarily in North America, Europe, and Israel.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Corporate Venture Capital
- Founded
- Founded in 2004
- Approximate age
- About 22 years
- Structured capabilities
- Funder
- Last reviewed
- May 5, 2026
Official channels
Find Esperante elsewhere
Open the official website or a supported primary organization account.
Capability profile
Esperante as a funder
Investment thesis
Esperante focuses on investing in life sciences companies, particularly in clinical-stage therapeutics and diagnostics, leveraging its operational expertise in pharmaceuticals to drive successful outcomes.
Focus narrative
Esperante focuses on investing in pharmaceutical companies entering Phase 2b to Phase 3 clinical development. The firm invests between EUR 500,000 and EUR 5,000,000 in syndication with other investors, aiming for liquidity outcomes within three years. Key therapeutic areas of interest include endocrinology, fertility, gastroenterology, gynaecology, hepatology, infectious disease, oncology, ophthalmology, otology, urology/uro-oncology, and women’s health.
Value beyond capital
Esperante adds value to its portfolio companies through its deep operational expertise in pharmaceuticals, providing support in development, manufacturing, regulatory affairs, and commercialization strategies, which can enhance the likelihood of successful exits.
Terms and economics
- Typical check
- $500,000–$5,000,000
Focus and fit
- Stages
- Series A · Series B · Series C · Growth Equity
- Sectors
- Biotech · Healthcare · Diagnostics
- Regions
- North AmericaEurope
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 25
- Recorded notable exits
- Thiakis, Pinnacle Biologics, Haemostatix, and Altacor
Portfolio context
Notable portfolio companies include: Cara Therapeutics: Known for its FDA-approved product, Korsuva, which has been launched in the US. Medicenna Therapeutics Corp.: A clinical-stage immunotherapy company focused on developing Superkines. Altimmune: Another company within the portfolio, details on its specific focus were not provided. AMLo Biosciences: Developing a prognostic test for early-stage melanoma risk stratification. Acousia Therapeutics: Developing small-molecule therapeutics for hearing loss, including ACOU085. Spiral Therapeutics: Developing therapies for inner-ear disorders and drug delivery technology.
Common questions
What to know about Esperante
Upseed classifies Esperante under the Corporate Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
May 5, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.